Literature DB >> 2901930

Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers.

B Delhotal-Landes1, B Flouvat, F Liote, L Abel, P Meyer, P Vinceneux, C Carbon.   

Abstract

The reciprocal effects on pharmacokinetic parameters after a single oral dose of the nonsteroidal antiinflammatory drugs (NSAIDs) indomethacin and sulindac and repeated oral doses of the H2-receptor antagonists cimetidine and ranitidine were determined in two groups of nine healthy subjects each (indomethacin and sulindac groups). Administration of NSAIDs increased the AUC and decreased the oral clearance and apparent volume of distribution of the H2-receptor antagonists without modifying their t1/2. Urinary data and observed modifications in ranitidine and cimetidine metabolites seem to justify a greater increase of H2-receptor antagonist bioavailability with indomethacin (p less than 0.05) than with sulindac (NS). The administration of ranitidine significantly reduced the sulindac volume of distribution without modifying its clearance, which caused an increase in the maximum concentration and a decrease in the t1/2 (p less than 0.05). The effects of cimetidine on the two NSAIDs were more intense than the effect of ranitidine: the decrease in sulindac volume of distribution (p less than 0.02) was accompanied by a significant reduction in sulindac clearance (p less than 0.05). AUC and urinary amounts of sulindac's sulfone metabolite were decreased. These results show that NSAIDs increased the bioavailability of H2-receptor antagonists, and that the latter drugs decrease the volume of distribution of NSAIDs. Furthermore, cimetidine modifies the oxidation metabolism of sulindac.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901930     DOI: 10.1038/clpt.1988.178

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Interactions between non-steroidal anti-inflammatory drugs and H2-receptor antagonists or prostaglandin analogues.

Authors:  J S Dixon; M C Page
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

2.  A lack of pharmacokinetic interaction between ranitidine and piroxicam.

Authors:  J S Dixon; L F Lacey; M E Pickup; S J Langley; M C Page
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 4.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

5.  Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers.

Authors:  C Alioth; R A Blum; D T D'Andrea; G M Kochak; L Teng; B A Ziehmer; J J Schentag; K K Chan
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

6.  Cimetidine does not alter the clearance or plasma binding of tenidap in healthy male volunteers.

Authors:  K D Wilner; M J Gardner
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

Review 7.  Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  J R Brouwers; P A de Smet
Journal:  Clin Pharmacokinet       Date:  1994-12       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.